Bram Vanparys joined Gimv in 2018.
Bram has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam.
Bram has a successful track record in Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent), Q-Biologicals (acquired by Amatsigroup, now Eurofins), Calypso Biotech and iOmx.
Today, Bram acts as a board member for portfolio companies ImCheck Therapeutics (France), iSTAR Medical (Belgium), Kinaset Therapeutics (US) and Topas Therapeutics (Germany).
Bram is trained as a PhD in biotechnology (University of Ghent, Belgium) and has an executive MBA from Vlerick Business School (Belgium).